Free Trial

PetVivo Q1 2024 Earnings Report

PetVivo logo
$0.77 +0.04 (+6.04%)
As of 01/30/2025 01:53 PM Eastern

PetVivo EPS Results

Actual EPS
-$0.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PetVivo Revenue Results

Actual Revenue
$0.12 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PetVivo Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

PetVivo Earnings Headlines

PetVivo appoints Mike Eldred as commercialization, operations advisor
Your chance to get on the next “60-Second Trade”
Even retirees are being forced back to work just to keep up. And if you're waiting for help from the Fed or government... Well, you might be waiting a very long time. But Roger Scott has uncovered something interesting... What if there was a way to fight back against inflation? A simple method you could use right from your phone...
See More PetVivo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PetVivo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PetVivo and other key companies, straight to your email.

About PetVivo

PetVivo (NASDAQ:PETV), a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.

View PetVivo Profile

More Earnings Resources from MarketBeat